1-4 of 4
Paola Cerroni
Close
Sort by
Journal Articles

Antitumour Activity of Bortezomib-Pegylated Liposomal Doxorubicine Association as Salvage Therapy in Multiple Myeloma Patients.

Giulia Braccalenti, M.D., Pasqualinda Ferrara, Ph.D., Marta Gubbiotti, M.D., Paola Cerroni, M.D., Lorenzo Falchi, M.D., Debora Luzi, M.D., Roberta Martiniani, M.D., Roberta Pace, M.D., Anna Marina Liberati, MD
Journal: Blood
Blood (2007) 110 (11): 4832.
https://doi.org/10.1182/blood.V110.11.4832.4832
Published: 2007
Journal Articles

Persistent Molecular Remission in Patients Treated with Imatinib-IFNa Combination or Imatinib Monotherapy.

Monica Schippa, Enrico Gottardi, Debora Luzi, Lorenzo Falchi, Rita Emili, Ilaria Angeletti, Giorgia Desantis, Erminia Gentileschi, Paola Cerroni, Anna Marina Liberati
Journal: Blood
Blood (2006) 108 (11): 4784.
https://doi.org/10.1182/blood.V108.11.4784.4784
Published: 2006
Journal Articles

Antitumour Activity of Bortezomib-Pegylated Liposomal Doxorubicine Association: Results of an Ongoing Study in Multiple Myeloma Patients.

Giulia Braccalenti, Pasqualinda Ferrara, Marta Gubbiotti, Paola Cerroni, Rita Emili, Maria Grazia Morandi, Roberta Pace, Anna Marina Liberati
Journal: Blood
Blood (2006) 108 (11): 5116.
https://doi.org/10.1182/blood.V108.11.5116.5116
Published: 2006
Journal Articles

Has the 67 Ga-SPET a Role in Monitoring Hodgkin and Primary Mediastinal Lymphoma in the PET-FDG Age?.

Isabella Palumbo, Giorgia Desantis, Barbara Palumbo, Lorenzo Falchi, Paola Cerroni, Vincenzo Capparella, Michele Cianciulli, Renato Palumbo, Anna M. Liberati
Journal: Blood
Blood (2005) 106 (11): 4643.
https://doi.org/10.1182/blood.V106.11.4643.4643
Published: 2005